Glaukos Co. (NYSE:GKOS) Receives $129.82 Average Price Target from Analysts

Glaukos Co. (NYSE:GKOS) has earned an average recommendation of “Moderate Buy” from the eleven analysts that are presently covering the firm, MarketBeat Ratings reports. Three investment analysts have rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average 1-year target price among analysts that have covered the stock in the last year is $129.82.

A number of equities analysts have commented on the company. Needham & Company LLC boosted their price objective on Glaukos from $131.00 to $137.00 and gave the stock a “buy” rating in a research note on Thursday, August 1st. BTIG Research increased their price objective on shares of Glaukos from $131.00 to $139.00 and gave the stock a “buy” rating in a report on Wednesday, August 28th. Piper Sandler raised their price objective on shares of Glaukos from $110.00 to $140.00 and gave the company an “overweight” rating in a research report on Thursday, August 1st. Wells Fargo & Company increased their price target on shares of Glaukos from $120.00 to $135.00 and gave the company an “overweight” rating in a research note on Thursday, August 1st. Finally, Morgan Stanley upped their price objective on Glaukos from $100.00 to $120.00 and gave the stock an “equal weight” rating in a report on Monday, July 15th.

Glaukos Stock Down 1.0 %

GKOS opened at $126.90 on Friday. Glaukos has a twelve month low of $59.22 and a twelve month high of $136.60. The firm has a market cap of $6.39 billion, a price-to-earnings ratio of -44.06 and a beta of 1.02. The firm’s 50-day simple moving average is $127.11 and its 200-day simple moving average is $115.98. The company has a debt-to-equity ratio of 0.19, a quick ratio of 4.67 and a current ratio of 5.48.

Glaukos (NYSE:GKOS) last posted its quarterly earnings data on Wednesday, July 31st. The medical instruments supplier reported ($0.52) earnings per share for the quarter, hitting the consensus estimate of ($0.52). The company had revenue of $95.70 million during the quarter, compared to analyst estimates of $88.86 million. Glaukos had a negative net margin of 47.39% and a negative return on equity of 22.51%. The company’s revenue was up 19.0% on a year-over-year basis. During the same quarter last year, the business posted ($0.55) earnings per share. Equities research analysts anticipate that Glaukos will post -2.18 EPS for the current fiscal year.

Insider Buying and Selling at Glaukos

In related news, Director Gilbert H. Kliman sold 3,000 shares of the company’s stock in a transaction on Monday, September 9th. The shares were sold at an average price of $130.67, for a total value of $392,010.00. Following the completion of the sale, the director now owns 32,336 shares in the company, valued at $4,225,345.12. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In related news, COO Joseph E. Gilliam sold 5,000 shares of the business’s stock in a transaction on Wednesday, August 21st. The shares were sold at an average price of $129.36, for a total value of $646,800.00. Following the sale, the chief operating officer now directly owns 102,169 shares of the company’s stock, valued at approximately $13,216,581.84. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Gilbert H. Kliman sold 3,000 shares of the stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $130.67, for a total value of $392,010.00. Following the transaction, the director now owns 32,336 shares of the company’s stock, valued at approximately $4,225,345.12. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 39,250 shares of company stock valued at $4,825,873. 6.40% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Glaukos

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Caldwell Sutter Capital Inc. raised its stake in shares of Glaukos by 5,860.0% during the 1st quarter. Caldwell Sutter Capital Inc. now owns 1,490 shares of the medical instruments supplier’s stock worth $140,000 after purchasing an additional 1,465 shares in the last quarter. GAMMA Investing LLC increased its position in Glaukos by 68.8% during the second quarter. GAMMA Investing LLC now owns 1,192 shares of the medical instruments supplier’s stock worth $141,000 after buying an additional 486 shares during the last quarter. Fifth Third Wealth Advisors LLC bought a new stake in Glaukos in the second quarter valued at approximately $187,000. Brighton Jones LLC acquired a new stake in shares of Glaukos in the second quarter valued at approximately $208,000. Finally, Procyon Advisors LLC bought a new position in shares of Glaukos during the 3rd quarter worth approximately $210,000. 99.04% of the stock is currently owned by institutional investors and hedge funds.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.